NCT04784247View on ClinicalTrials.gov

Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Advanced Sarcoma
Interventions
DRUG

Lenvatinib

20mg daily (two 10mg lenvatinib capsules) taken orally

DRUG

Pembrolizumab

(200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Cancer Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Parker Institute for Cancer Immunotherapy

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER